Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2010, Article ID 612619, 7 pages
Review Article

Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease

1Boehringer Ingelheim Pharma GmbH & Co. KG, Pharmaceutical Development, 88397 Biberach, Germany
2Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Research, 88397 Biberach, Germany
3Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Metabolism and Pharmacokinetics, 88397 Biberach, Germany
4Department of Neurology, Deutsche Klinik für Diagnostik, Aukammallee 33, 65191 Wiesbaden, Germany

Received 16 September 2010; Accepted 10 November 2010

Academic Editor: Katherine Grosset

Copyright © 2010 Wolfram Eisenreich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Pramipexole, the most commonly prescribed dopamine agonist worldwide, meanwhile serves as a reference substance for evaluation of new drugs. Based on numerous clinical data and vast experiences, efficacy and safety profiles of this non-ergoline dopamine agonist are well characterized. Since October 2009, an extended-release formulation of pramipexole has been available for symptomatic treatment of Parkinson's disease. Pramipexole administration can be cut down from three times to once a day due to the newly developed extended-release formulation. This is considerable progress in regard to minimizing pill burden and enhancing compliance. Moreover, the 24 h continuous drug release of the once-daily extended-release formulation results in fewer fluctuations in plasma concentrations over time compared to immediate-release pramipexole, given three times daily. The present study summarizes pharmacokinetics and all essential pharmacological and clinical characteristics of the extended-release formulation. In addition, it provides all study data, available so far, with regard to transition and de-novo administration of extended-release formulation for patients with Parkinson's disease. It further compares efficacy and safety data of immediate-release pramipexole with the extended-release formulation of pramipexole.